TRAIL R-2/DR5, oplosbaar

TRAIL Receptor-1/DR4 and TRAIL Receptor-2/DR5 belong to the TNFR superfamily of transmembrane proteins and contain a cytoplasmic "death domain", which can activate the cell's apoptotic machinery. These receptors are activated by binding to either membrane anchored or soluble TRAIL/Apo2L. Recombinant human soluble TRAIL Receptor-2/DR5 is a 14.9 kDa protein (133 amino acid residues) consisting of the TNFR homologous, cysteine rich portion of the extracellular domain.

TNFRSF10B; DR5; CD262; KILLER; TRICK2; TRICKB; ZTNFR9; TRAILR2; TRICK2A; TRICK2B; TRAIL-R2; KILLER/DR5

8795

O14763

NP_003833.4

NM_003842.4

8p22-p21

Human

Human

MESALITQQD LAPQQRVAPQ QKRSSPSEGL CPPGHHISED GRDCISCKYG QDYSTHWNDL LFCLRCTRCD SGEVELSPCT TTRNTVCQCE EGTFREEDSP EMCRKCRTGC PRGMVKVGDC TPWSDIECVH KES

< 0.1 ng/µg of protein (< 1EU/µg)

> 98% by SDS-PAGE & HPLC analyses

STRAIL Receptor 2 reduced the production of LPS-induced TNF by its ability to neutralize endogenous TRAIL in fresh human PBMC. In this assay, endogenous TRAIL is induced during a 24 hour exposure to LPS (10 ng/mL) but in the presence of sTRAIL Receptor 2, TRAIL-induced TNF is suppressed.

133

Lyophilized

14.9 kDa

E. coli